natgillin/translations-raw huggingface dataset:
• If you have any further questions, ask your healthcare worker. 
• Če imate dodatna vprašanja, se posvetujte z zdravstvenim delavcem.
Immune globulin (IG), blood or plasma transfusions should not be given concomitantly with Ervebo. 
Sočasno s cepivom Ervebo se ne sme dajati imunoglobulinov (IG) ali transfuzij krvi ali plazme.
Transmission of vaccine virus through close personal contact is accepted as a theoretical possibility. 
Prenos cepilnega virusa s tesnim osebnim stikom velja kot teoretična možnost.
Vaccine administrators should counsel vaccinees to continue to protect themselves with the following measures: 
Osebe, ki dajejo cepivo, morajo cepljenim osebam naročiti, naj se še naprej varujejo z naslednjimi ukrepi:
• Use soap and water when hands are soiled with dirt, blood, or other body fluids. 
• Uporabljajte milo in vodo, če so roke onesnažene z umazanijo, krvjo ali drugimi telesnimi tekočinami.
Standard precautions, as outlined by WHO, include the following: 
Običajni previdnostni ukrepi, kot jih navaja Svetovna zdravstvena organizacija, obsegajo:
• The vaccine is stored frozen at -80°C to -60°C and should be removed from the freezer and thawed in less than 4 hours until no visible ice is present. 
• Cepivo je treba shranjevati zamrznjeno pri temperaturi od -80 do -60 °C ter ga je treba vzeti iz zmrzovalnika in odtaliti v manj kot 4 urah, dokler ni več vidnega ledu.
Women who are able to become pregnant should use an effective method of birth control. 
Ženske, ki lahko zanosijo, morajo uporabljati učinkovito kontracepcijsko metodo.
This is because of a possibility that you could pass on the virus in the vaccine to the animals. 
To je potrebno, ker viruse iz cepiva lahko prenesete na živali.
In 6 out of 18 subjects tested, the vaccine virus was detected in rashes (described as dermatitis, vesicles or cutaneous vasculitis lesions) suggesting a virally mediated process post-vaccination. 
Pri 6 od 18 testiranih oseb so v izpuščajih (opisanih kot dermatitis, vezikli ali kožne vaskulitične lezije) našli cepilni virus; to kaže na virusno pogojeno dogajanje po cepljenju.
30938 Burgwedel Germany 
30938 Burgwedel Nemčija
• Hand washing 
• umivanjem rok
Solution for 1 dose in a vial (type I glass) with a stopper (chlorobutyl) and a flip-off plastic cap with aluminium seal. 
Raztopina za 1 odmerek v viali (steklo tipa I) z zamaškom (klorobutil) in snemno plastično zaporko z aluminijsko zaporo.
You might have a weak immune system if: 
Šibek imunski sistem imate lahko:
• Items that may have come in contact with an infected person's blood or body fluids (such as clothes, bedding, needles, and medical equipment). 
• Predmetom, ki so morda bili v stiku s krvjo ali telesnimi tekočinami okužene osebe (na primer z oblačili, posteljnino, iglami in medicinsko opremo).
In this trial, 9,096 subjects ≥18 years of age who were considered CCCs of an index case with laboratory-confirmed EVD were randomized to immediate (4,539 subjects in 51 clusters) or 21 days delayed (4,557 subjects in 47 clusters) vaccination with Ervebo. 
V tem preskušanju so 9.096 preiskovancev, starih ≥ 18 let, ki so bili domnevno KKK indeksnega primera z laboratorijsko potrjeno ebolo, randomizirali ali na takojšnje (4.539 preiskovancev v 51 gručah) ali za 21 dni odloženo (4.557 preiskovancev v 47 gručah) cepljenje s cepivom Ervebo.
Transmission of vaccine virus through close contact with livestock is accepted as a theoretical possibility. 
Prenos cepilnega virusa s tesnim stikom z živino velja kot teoretična možnost.
However, as a precaution, vaccinees should attempt to avoid exposure of livestock to blood and bodily fluids for at least 6 weeks following vaccination to avoid the theoretical risk of spread of the vaccine virus. 
Toda iz previdnosti naj se cepljene osebe poskusijo izogibati izpostavljenosti živine krvi in telesnim tekočinam vsaj 6 tednov po cepljenju, da bi preprečili teoretično tveganje za širjenje cepilnega virusa.
• If you have ever had an allergic reaction to a vaccine or medicine, talk to your healthcare worker before you receive this vaccine. 
• Če se vam je kdaj pojavila alergijska reakcija na kakšno cepivo ali zdravilo, se pred cepljenjem posvetujte z zdravstvenim delavcem.
The most common injection-site adverse reactions were injection-site pain (70.3%), swelling (16.7%) and erythema (13.7%). 
Najpogostejši neželeni učinki na mestu injiciranja so bili bolečina na mestu injiciranja (70,3 %), oteklost (16,7 %) in eritem (13,7 %).
No studies on the effects of Ervebo on the ability to drive and use machines have been performed. 
Študij o vplivih cepiva Ervebo na sposobnost vožnje in upravljanja strojev niso izvedli.
• Pain, swelling, or redness at the injection site. 
• bolečina, oteklost ali pordelost na mestu injiciranja.
Following vaccination with Ervebo, individuals may test positive for Ebola glycoprotein (GP) nucleic acids, antigens, or antibodies against Ebola GP, which are targets for certain Ebola diagnostic tests. 
Osebe, cepljene s cepivom Ervebo, imajo lahko po cepljenju pozitiven izvid testa za nukleinske kisline, antigene glikoproteina (GP) Ebola ali protitelesa proti GP Ebola, na katerih temeljijo nekateri diagnostični testi za ebolo.
The MAH should provide additional qualification data for the critical reagent used in the identity test (quality control release test for AS and FP). 
Imetnik dovoljenja za promet s cepivom mora predložiti dodatne podatke o kvalifikaciji ključnega reagenta, uporabljenega pri preskusu identifikacije (preskus sproščanja kontrole kakovosti za učinkovino in gotovo zdravilo).
In general, these reactions were reported within 7 days after vaccination, were mild to moderate in intensity, and had short duration (less than 1 week). 
Na splošno so o teh učinkih poročali v prvih 7 dneh po cepljenju, bili so blagi do zmerni in kratkotrajni (manj kot 1 teden).
The safety profile of Ervebo in children and adolescents 6 to17 years of age was generally similar to that observed in adults. 
Varnostne značilnosti cepiva Ervebo pri otrocih in mladostnikih, starih od 6 do 17 let, so bile na splošno podobne tistim, ki so jih ugotovili pri odraslih.
This trial compared Ervebo to normal saline placebo in 1,000 adults ≥18 years of age in Liberia. 
V tem preskušanju so primerjali cepivo Ervebo in placebo (fizološko raztopino) pri 1.000 odraslih, starih ≥ 18 let v Liberiji.
The Per-Protocol Immunogenicity Population was the primary population for the immunogenicity analyses in Protocol 012 and includes all subjects who were compliant with the protocol, received vaccination, were seronegative at Day 1, and had a serum sample at one or more timepoints collected within an acceptable day range. 
Populacija imunogenosti po-protokolu je bila primarna populacija za analize imunogenosti v Protokolu 012; obsegala je vse preiskovance, ki so upoštevali protokol, bili cepljeni, bili seronegativni 1. dan in so imeli vzorec seruma na eni ali več časovnih točkah odvzet v sprejemljivem razponu dni.
Administration of immune globulins, blood or plasma transfusions administered 3 months before or up to 1 month after Ervebo administration may interfere with the expected immune response. 
Uporaba imunoglobulinov ali transfuzija krvi ali plazme v 3 mesecih pred uporabo cepiva Ervebo ali do 1 mesec po njegovi uporabi lahko zmoti pričakovani imunski odziv.
Plan to donate blood • Do not donate blood for at least 6 weeks after you receive this vaccine. 
Če nameravate darovati kri • Ne darujte krvi vsaj 6 tednov po tem, ko prejmete to cepivo.
Ervebo should be administered by a trained healthcare worker. 
Cepivo Ervebo mora aplicirati usposobljen zdravstveni delavec.
Ervebo is given by a healthcare worker. 
Cepivo Ervebo vam bo dal zdravstveni delavec.
This vaccine might not protect everyone who receives it and the length of time you are protected from Ebola by Ervebo is not known. 
Cepljenje s cepivom Ervebo morda ne bo zaščitilo vseh oseb, ki ga dobijo, in trajanje zaščite, ki vam jo cepivo Ervebo zagotavlja pred ebolo, ni znano.
The MAH should provide comprehensive comparability data confirming that the commercial product manufactured at the Burgwedel site is representative of the material used in the clinical trials. 
Imetnik dovoljenja za promet s cepivom mora predložiti izčrpne primerjalne podatke, ki dokazujejo, da je zdravilo, namenjeno trženju in izdelano na lokaciji Burgwedel, reprezentativno za zdravilo, uporabljeno v kliničnih preskušanjih.
What Ervebo is and what it is used for What you need to know before you receive Ervebo How Ervebo is given 
Kaj je cepivo Ervebo in za kaj ga uporabljamo Kaj morate vedeti, preden boste prejeli cepivo Ervebo Kako boste prejeli cepivo Ervebo Možni neželeni učinki
Baseline seropositivity, gamma irradiation of specimens to reduce risk of wild-type Ebola virus infection of laboratory workers, and other factors may impact the immune response to vaccine, which results in a higher immune response in Protocol 012. 
Na imunski odziv na cepivo lahko vplivajo izhodiščna seropozitivnost, obsevanje vzorcev z žarki gama za zmanjšanje tveganja okužbe laboratorijskih delavcev z divjim tipom virusa Ebola in drugi dejavniki; rezultat tega je večji imunski odziv v Protokolu 012.
Over 93.8% of vaccine recipients met seroresponse criteria defined as a ≥2-fold increase from baseline and ≥200 EU/mL at any time post-vaccination by GPELISA and over 80.4% of subjects met seroresponse criteria defined as a ≥4-fold increase from baseline at any time post-vaccination by PRNT. 
Več kot 93,8 % prejemnikov cepiva je doseglo merilo serološkega odziva, opredeljeno kot ≥ 2-kratno povečanje od izhodišča in ≥ 200 E.e./ml kadar koli po cepljenju določeno z GP-ELISA, in več kot 80,4 % preiskovancev je doseglo merilo serološkega odziva, opredeljeno kot ≥ 4-kratno povečanje od izhodišča kadar koli po cepljenju določeno s PRNT.
The CHMP having considered the application is of the opinion that the risk-benefit balance is favourable to recommend the granting of the conditional marketing authorisation as further explained in the European Public Assessment Report. 
• pridobitvi pogojnega dovoljenja za promet z zdravilom Odbor za zdravila za uporabo v humani medicini (CHMP) po obravnavi vloge meni, da je razmerje med tveganji in koristmi ugodno, da lahko priporoči izdajo pogojnega dovoljenja za promet z zdravilom, kot je podrobneje razloženo v evropskem javnem poročilu o oceni zdravila.
• Ervebo is a solution for injection. 
• Cepivo Ervebo je raztopina za injiciranje.
Close monitoring is recommended following vaccination for the early signs of anaphylaxis or anaphylactoid reactions. 
Po cepljenju je priporočljivo skrbno spremljanje glede možnih zgodnjih znakov anafilaksije ali anafilaktoidnih reakcij.
Therefore, diagnostic testing for Ebola should target non-GP sections of the Ebola virus. 
Zato mora diagnostično testiranje za ebolo temeljiti na neglikoproteinskih odsekih virusa Ebola.
The vaccine should not be mixed in the same syringe with any other vaccines or medicinal products. 
Cepiva se v isti injekcijski brizgi ne sme mešati z nobenim drugim cepivom ali zdravilom.
Over 80.1% of subjects continued to meet the seroresponse criteria for GP-ELISA and over 63.5% of vaccine recipients continued to meet seroresponse criteria for PRNT at 12 months. 
Po 12 mesecih je merila serološkega odziva še izpolnjevalo več kot 80,1 % preiskovancev glede na GP-ELISA in več kot 63,5 % prejemnikov cepiva glede na PRNT.
Ervebo has no or negligible influence on the ability to drive and use machines. 
Cepivo Ervebo nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
Do not receive this vaccine at the same time that you get blood or blood products. 
Če je predvideno, da boste prejeli kri ali krvne izdelke Tega cepiva ne smete dobiti ob istem času, ko dobite kri ali kakšne krvne izdelke.
One dose (1 mL): Ebola Zaire Vaccine (rVSVΔG-ZEBOV-GP, live attenuated) ≥72 million pfu 
En odmerek (1 ml): cepivo proti virusu Ebola Zaire (rVSVΔG-ZEBOV-GP, z živimi oslabljenimi virusi) ≥ 72 milijonov pfu
In clinical trials with reports of arthritis, the median onsets were between 10 and 12 days (range from 0 to 25 days). 
V kliničnih preskušanjih, kjer so poročali o artritisu, je bil mediani čas do njegovega nastopa med 10 in 12 dni (v razponu od 0 do 25 dni).
• If you have a fever (high temperature), you should talk to your healthcare worker before receiving Ervebo. 
• Če imate zvišano telesno temperaturo (vročino), se posvetujte z zdravstvenim delavcem, preden prejmete cepivo Ervebo.
What Ervebo looks like and contents of the pack 
Izgled cepiva Ervebo in vsebina pakiranja
Of those 9,096 subjects, 4,160 received Ervebo (2,119 subjects were vaccinated in the immediate arm and 2,041 subjects were vaccinated in the delayed arm). 
Od teh 9.096 preiskovancev jih je 4.160 prejelo cepivo Ervebo (2.119 preiskovancev je bilo cepljenih v skupini s takojšnjim cepljenjem, 2.041 pa v skupini z odloženim cepljenjem).
Protocol 009 Partnership for Research on Ebola Vaccines in Liberia (PREVAIL) was a Phase 2 randomized, double-blind, placebo-controlled trial which evaluated the safety and immunogenicity of Ebola vaccine candidates including Ervebo. 
Protokol 009 PREVAIL (Partnership for Research on Ebola Vaccines in Liberia) je bilo randomizirano, dvojno slepo, s placebom nadzorovano preskušanje 2. faze, ki je ovrednotilo varnost in imunogenost kandidatnih cepiv proti eboli, vključno s cepivom Ervebo.
The vaccine should appear as a colourless to slightly brownish-yellow liquid with no particulates visible. 
Cepivo mora biti brezbarvna do rahlo rjavorumena raztopina brez vidnih delcev.
All healthcare workers and other ancillary providers who have been vaccinated should not alter their practices with regard to safe injection, hygiene, and personal protective equipment (PPE) after vaccination. 
Zdravstveni delavci in drugo pomožno osebje, ki so bili cepljeni, po cepljenju ne smejo spreminjati ravnanja glede varnega injiciranja, higiene in opreme za osebno zaščito.
Ervebo administered to female rats had no effects on development or behaviour of the offspring. 
Cepivo Ervebo, uporabljeno pri podganjih samicah, ni vplivalo na razvoj ali vedenje potomstva.
This vaccine contains less than 1 mmol (23 mg) of sodium per dose. 
Cepivo vsebuje manj kot 1 mmol (23 mg) natrija na odmerek.
• You can also catch Ebola from things that have touched the blood or body fluids of a person or animal with Ebola (like clothes or objects in direct contact). 
• Prav tako se lahko ebole nalezete preko predmetov, ki so bili v stiku s krvjo ali telesnimi tekočinami osebe ali živali, obolele za ebolo (npr. preko oblačil ali predmetov, ki so bili v neposrednem stiku).
Vaccine administrators should counsel vaccinees to continue to protect themselves with adequate measures. 
Osebe, ki dajejo cepivo, morajo cepljenim osebam naročiti, naj se še naprej varujejo z ustreznimi ukrepi.
• Ervebo should not be mixed in the same syringe with any other vaccines or medicinal products. 
• Cepiva Ervebo ne smete v isti injekcijski brizgi mešati z nobenim drugim cepivom ali zdravilom.
The vaccine virus is a Genetically Modified Organism (GMO). 
Cepilni virus je genetsko spremenjen organizem (GSO).
Protocol 012 was a Phase 3 randomized, double-blind, placebo-controlled trial which evaluated the safety and immunogenicity of three consistency lots and a high dose lot (approximately five times higher than the dose in consistency lots and dose used in other Phase 2/3 trials) of Ervebo compared to normal saline placebo. 
Protokol 012 je bilo randomizirano, dvojno slepo, s placebom nadzorovano preskušanje 3. faze, ki je ovrednotilo varnost in imunogenost treh konsistenčnih serij (consistency lots) in serije z velikim odmerkom (približno petkrat večji odmerek od odmerka v konsistenčnih serijah in odmerka, uporabljenega v drugih preskušanjih 2./3.
Like all vaccines, Ervebo can cause side effects, although not everybody gets them. 
Kot vsa cepiva ima lahko tudi cepivo Ervebo neželene učinke, ki pa se ne pojavijo pri vseh cepljenih osebah.
Protocol 010 (Ring vaccination study) was a Phase 3 open-label cluster-randomized trial of ring vaccination (vaccinating contacts and contacts of contacts [CCCs] of index Ebola cases) which evaluated efficacy and safety of Ervebo in Guinea. 
Protokol 010 (študija krožnega cepljenja) je bilo odprto, gručno randomizirano preskušanje 3. faze s krožnim cepljenjem (cepljenje kontaktov in kontaktov kontaktov [KKK]) indeksnih primerov obolelih za ebolo), ki je ovrednotila učinkovitost in varnost cepiva Ervebo v Gvineji.
The Full Analysis Set population was the primary population for the immunogenicity analyses in Protocols 009 and 011 and consists of all vaccinated subjects with serology data and had a serum sample collected within an acceptable day range. 
Populacija celotnega nabora za analizo (FAS - full analysis set) je bila primarna populacija za analize imunogenosti v Protokolih 009 in 011; obsegala je vse cepljene preiskovance, ki so imeli serološke podatke in pri katerih je bil vzorec seruma odvzet v sprejemljivem razponu dni.
Across the Phase 1 through Phase 3 trials, 234 children and adolescents 6 to 17 years of age received a dose of Ervebo. 
V preskušanjih od 1. do 3. faze je odmerek cepiva Ervebo prejelo 234 otrok in mladostnikov, starih od 6 do 17 let.
If you are not sure, talk to your healthcare worker. 
Če ste negotovi, se posvetujte z zdravstvenim delavcem.
• Because Ervebo does not contain the whole Ebola virus, it cannot give you Ebola virus disease. 
• Ker cepivo Ervebo ne vsebuje celih virusov, zaradi njega ne morete zboleti za ebolo.
Uncertainties remain as to the level, duration and type of protection given the methodological limitations and the exceptional circumstances experienced during the trial. 
Glede na metodološke omejitve in izredne okoliščine, ki so vladale med preskušanjem, ostajajo raven, trajanje in vrsta zaščite negotove.
In different trials, rash was reported with median onsets of 7.5 to 10.5 days (range from 0 to 47 days). 
V različnih preskušanjih, v katerih so poročali o izpuščajih, je bil mediani čas do njegovega nastopa od 7,5 do 10,5 dneva (v razponu od 0 do 47 dni).
• Basic hand hygiene 
• osnovno higieno rok
• Safe sex 
• varno spolnostjo
Rash was characterized in a variety of ways including generalized rash (2.3%), vesicular rash (0.5%), dermatitis (0.3%), or cutaneous vasculitis (0.01%) in clinical trials. 
V kliničnih preskušanjih se je izpuščaj pojavil v različnih oblikah, vključno z generaliziranim izpuščajem (2,3 %), vezikularnim izpuščajem (0,5 %), dermatitisom (0,3 %) ali kožnim vaskulitisom (0,01 %).
Have a weak immune system 
Če imate šibek imunski sistem
The MAH should develop and introduce an active substance in-process control for total protein with appropriate acceptance. 
Imetnik dovoljenja za promet s cepivom mora v procesu izdelave učinkovine razviti in uvesti medprocesno kontrolo glede skupnih proteinov z ustrezno sprejemljivostjo preskusa.
Individuals who develop vesicular rash after receiving the vaccine should cover the vesicles until they heal to minimize the risk of possible transmission of vaccine virus through open vesicles. 
Osebe, ki se jim po cepljenju pojavi vezikularen izpuščaj, morajo mehurčke pokrivati, dokler se ne pozdravijo, da bi tako zmanjšali možnost za prenos cepilnega virusa skozi odprte mehurčke.
Process and batch data from at least 3 representative FP batches should be provided. 
Predložiti je treba procesne podatke in podatke serij vsaj 3 reprezentativnih serij učinkovine.
Vaccine virus RNA has been detected by PCR in the plasma of most of the adult subjects. 
RNA cepilnega virusa so z verižno reakcijo s polimerazo (PCR - polymerase chain reaction) zaznali v plazmi večine odraslih preiskovancev.
Safety and efficacy of Ervebo have not been assessed in immunocompromised individuals. 
Varnost in učinkovitost cepiva Ervebo pri imunsko oslabelih osebah nista ugotovljeni.
Use of Ervebo with other vaccines is not recommended. 
Cepiva Ervebo ni priporočljivo uporabljati z drugimi cepivi.
This is because you could pass on the virus in the vaccine to them through your body fluids. 
To je potrebno, ker viruse iz cepiva lahko prenesete nanje s svojimi telesnimi tekočinami.
As there are no data on co-administration of Ervebo with other vaccines, the concomitant use of Ervebo with other vaccines is not recommended. 
O sočasni uporabi cepiva Ervebo z drugimi cepivi ni podatkov, zato sočasna uporaba cepiva Ervebo z drugimi cepivi ni priporočljiva.
• Avoid contact with bats and non-human primates or blood, fluids and raw meat prepared from these animals (bushmeat) or meat from an unknown source. 
• izogibanjem stikom z netopirji in nehumanimi primati ter tudi stikom s krvjo, tekočinami in surovim mesom teh živali in z mesom neznanega izvora.
Vaccine virus might be present in biological fluids such as blood, urine, saliva, semen, vaginal fluids, aqueous humor, breast milk, faeces, sweat, amniotic fluid, and placenta. 
Cepilni virus je lahko prisoten v bioloških tekočinah, kot so kri, urin, slina, seme, nožnična tekočina, očesna vodica, materino mleko, blato, znoj, amnijska tekočina in placenta.
Transient decreases in counts of lymphocytes, neutrophils and total white blood cells in the first 3 days following vaccination have been observed very commonly in Phase 1/2 studies; these events generally resolved after the first week post-vaccination. 
faze so zelo pogosto opažali prehodno zmanjšanje števila limfocitov, nevtrofilcev in celotnega števila levkocitov v prvih 3 dneh po cepljenju; ti učinki so na splošno minili po prvem tednu po cepljenju.
However, once thawed, the vaccine can be stored for up to 14 days at 2°C to 8°C before use. 
Toda ko je cepivo odtajano, ga je mogoče pred uporabo shranjevati do 14 dni pri temperaturi od 2 do 8 °C.
People catch Ebola from people or animals who are infected with Ebola or who died from Ebola. 
Ljudje se bolezni ebola nalezejo od drugih ljudi s to boleznijo, od umrlih za to boleznijo, ali od živali, okuženih z njo.
The bandage may be removed when there is no visible fluid leakage. 
Povoj lahko odstranite, ko ni vidnega izcejanja tekočine.
The surface protein of the virus has been replaced with that of Zaire Ebola Virus (rVSVΔG-ZEBOV-GP). 
Beljakovina na površini virusa je nadomeščena z beljakovino virusa Ebola Zaire (rVSVΔG-ZEBOV-GP).
Summary of Geometric Mean Titers for the GP-ELISA from Protocols 009, 011 and 012 Clinical Trials 
Povzetek geometrične sredine titrov za GP-ELISA iz kliničnih preskušanj Protokol 009, 011 in 012
Pregnancy should be avoided for 2 months following vaccination. 
Ženska naj ne zanosi še 2 meseca po cepljenju.
Upon removal from the freezer, the product should be marked with both the date that it was taken out of the freezer and also a new discard date (in place of the labelled expiry date). 
Po odstranitvi iz zmrzovalnika je treba označiti datum, ko je bilo cepivo vzeto iz zmrzovalnika, in novi datum, ko je cepivo treba zavreči (na mesto označenega roka uporabnosti).
• Put the used plasters and bandages in a sealed container, if possible, and throw them away in the garbage bin to avoid having animals come into contact with the plasters and bandages. 
• Uporabljene obliže in povoje dajte v zapečaten vsebnik, če je to mogoče, in jih zavrzite v koš za smeti, da preprečite, da bi živali prišle v stik z obliži in povoji.
It is given as a single injection (dose of 1 mL) in the top of your arm or the outside of your thigh. 
Dobili ga boste v enkratni injekciji (1-ml odmerek) v nadlaket ali v zunanji del stegna.
There is no need to use antimicrobial soaps for washing hands. 
Umivanje rok s protimikrobnimi mili ni potrebno.
Immunization of subjects with the vaccine results in an immune response and protection from Zaire Ebola Virus Disease (EVD). 
Cepljenje preiskovancev s tem cepivom je povzročilo imunski odziv in zaščito pred boleznijo zaradi virusa Ebola Zaire.
There are limited amount of data (less than 300 pregnancy outcomes) from the use of Ervebo in pregnant women, or women who became pregnant after receiving the vaccine. 
Podatkov o uporabi cepiva Ervebo pri nosečnicah in ženskah, ki so zanosile po prejetju cepiva, je malo (manj kot 300 izidov nosečnosti).